iSpecimen Inc. (ISPC): Entry into a Material Definitive Agreement

iSpecimen Inc. (ISPC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On November 6, 2026, iSpecimen Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”) for the issuance and sale, in a priva

Event · Offering · closed
Instrument
Series D Convertible Preferred Stock
Gross proceeds
$400,000
Shares
500 shares
Price per share
$800 per share
Use of proceeds
working capital and general corporate purposes

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 9, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ISPC
Neutral
high confidence
Mentioned
$ISPC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ISPCNeutralLow
01

Why it matters

The infusion of $400k provides working capital but adds a convertible security that may dilute existing shareholders and affect price dynamics.

02

Market read

A micro‑cap capital raise with limited market impact; primarily relevant to current shareholders and short‑term traders.

03

What to watch

Potential future conversion of preferred shares could increase share count significantly if the stock price rises.

Relevance 6/10Novelty 7/10Timing: post‑closing of the November 6 offering

Background

SEC Form 8‑K filed on Nov 9, 2026 discloses iSpecimen's private placement of Series D convertible preferred stock.

Company-level read

Ticker impact

$ISPCNeutralHigh confidence
Context

iSpecimen Inc. entered a securities purchase agreement issuing 500 Series D convertible preferred shares for $400,000 gross proceeds.

Expected impact

likely modest downward pressure as dilution offsets the capital infusion, with upside potential if conversion terms become favorable.

Evidence & confidence

The raise is modest ($400k) for a micro‑cap, so market impact will be limited; however, the convertible feature and redemption rights create uncertainty that can weigh on the share price.

Market effects

Minimal impact on the broader biotech/clinical‑stage sector; the transaction is company‑specific.

No discernible effect on regional markets.

Limited to investors tracking micro‑cap capital raises.

Counterpoint

The raise could be seen as a sign of cash‑flow stress, suggesting further downside.

Key entities

  • iSpecimen Inc.

    Issuer of the Series D convertible preferred stock.

  • E.F. Hutton & Co.

    Exclusive placement agent for the offering.

Related articles

$BALYMedAI 8/10

BALLY’S CORPORATION SECURES $560 MILLION OF ADDITIONAL FINANCING Proceeds to be Used to Repay Outstanding Debt, for General Corporate Purposes and to Fund…

Bally's Corp (BALY) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 BALLY’S CORPORATION SECURES $560 MILLION OF ADDITIONAL FINANCING Proceeds to be Used to Repay Outstanding Debt, for General Corporate Purposes and to Fund Additional Development of Bally’s Chicago PROVIDENCE, R.I., November 17, 2026 — Bally’s Corporation (NYSE: BALY)